Generic Name: chlormethine hydrochloride
Brand Name: Ledaga
Manufacturer: Recordati Rare Diseases Canada Inc.
Therapeutic Area: T-cell lymphoma
Indications: For the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients.
Manufacturer Requested Reimbursement Criteria1: For the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) in adult patients.
Submission Type: Initial
Tumour Type: Lymphoma
NOC Status at Filing: Pre NOC
Project Status: Active
Companion Diagnostics: No
Fee Schedule1: Schedule A
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
|Call for patient/clinician input open||November 23, 2020|
|Call for patient/clinician input closed||January 22, 2021|
- Patient input submission received from Lymphoma Canada, Canadian Skin Patient Alliance and Cutaneous Lymphoma Foundation
|Submission received||December 21, 2020|
|Submission accepted||January 12, 2021|
|Review initiated||January 13, 2021|
|Draft CADTH review report(s) provided to sponsor for comment||April 16, 2021|
|Deadline for sponsors comments||April 27, 2021|
|CADTH responses on draft review report(s) provided to sponsor||May 31, 2021|
|Expert committee meeting (initial)||June 10, 2021|
|Draft recommendation issued to sponsor||June 22, 2021|
June 24, 2021
|Draft recommendation posted for stakeholder feedback||-|